Cosmo Pharmaceuticals Statistics
Total Valuation
CMOPF has a market cap or net worth of 902.30 million. The enterprise value is 749.98 million.
| Market Cap | 902.30M |
| Enterprise Value | 749.98M |
Important Dates
The next estimated earnings date is Wednesday, July 23, 2025.
| Earnings Date | Jul 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.94% |
| Shares Change (QoQ) | +3.31% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 8.52M |
Valuation Ratios
The trailing PE ratio is 6.54.
| PE Ratio | 6.54 |
| Forward PE | n/a |
| PS Ratio | 3.27 |
| PB Ratio | 1.73 |
| P/TBV Ratio | 2.79 |
| P/FCF Ratio | 5.52 |
| P/OCF Ratio | 5.37 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.09, with an EV/FCF ratio of 4.59.
| EV / Earnings | 5.44 |
| EV / Sales | 2.47 |
| EV / EBITDA | 4.09 |
| EV / EBIT | 4.43 |
| EV / FCF | 4.59 |
Financial Position
The company has a current ratio of 4.19, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.19 |
| Quick Ratio | 3.39 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 2,809.10 |
Financial Efficiency
Return on equity (ROE) is 29.31% and return on invested capital (ROIC) is 20.39%.
| Return on Equity (ROE) | 29.31% |
| Return on Assets (ROA) | 15.87% |
| Return on Invested Capital (ROIC) | 20.39% |
| Return on Capital Employed (ROCE) | 24.88% |
| Revenue Per Employee | 857,785 |
| Profits Per Employee | 428,384 |
| Employee Count | 322 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 3.27 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.29% in the last 52 weeks. The beta is 1.38, so CMOPF's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | -28.29% |
| 50-Day Moving Average | 66.17 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 34.80 |
| Average Volume (20 Days) | 215 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CMOPF had revenue of 276.21 million and earned 137.94 million in profits. Earnings per share was 8.40.
| Revenue | 276.21M |
| Gross Profit | 229.25M |
| Operating Income | 154.14M |
| Pretax Income | 158.78M |
| Net Income | 137.94M |
| EBITDA | 166.14M |
| EBIT | 154.14M |
| Earnings Per Share (EPS) | 8.40 |
Balance Sheet
The company has 148.01 million in cash and 2.28 million in debt, giving a net cash position of 145.73 million.
| Cash & Cash Equivalents | 148.01M |
| Total Debt | 2.28M |
| Net Cash | 145.73M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 522.92M |
| Book Value Per Share | 32.21 |
| Working Capital | 159.43M |
Cash Flow
In the last 12 months, operating cash flow was 168.14 million and capital expenditures -4.71 million, giving a free cash flow of 163.43 million.
| Operating Cash Flow | 168.14M |
| Capital Expenditures | -4.71M |
| Free Cash Flow | 163.43M |
| FCF Per Share | n/a |
Margins
Gross margin is 83.00%, with operating and profit margins of 55.81% and 49.94%.
| Gross Margin | 83.00% |
| Operating Margin | 55.81% |
| Pretax Margin | 57.49% |
| Profit Margin | 49.94% |
| EBITDA Margin | 60.15% |
| EBIT Margin | 55.81% |
| FCF Margin | 59.17% |
Dividends & Yields
CMOPF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 24.09% |
| Buyback Yield | -1.94% |
| Shareholder Yield | -1.94% |
| Earnings Yield | 15.29% |
| FCF Yield | 18.11% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CMOPF has an Altman Z-Score of 7.21.
| Altman Z-Score | 7.21 |
| Piotroski F-Score | n/a |